Analysis Of Income And Expense [Abstract]

Transgene - Filing #2810940

Concept 2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
Analysis of income and expense [abstract]
Material income and expense [abstract]
Research and development expense
29 588 EUR
32 168 EUR
Finance income (cost)
7 719 EUR
2 900 EUR
Selling, general and administrative expense [abstract]
General and administrative expense
6 987 EUR
7 912 EUR
Revenue and other operating income
7 900 EUR
10 344 EUR
Operating expense
37 947 EUR
40 248 EUR
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations
- EUR
7,000 EUR
- EUR
- EUR
- EUR
7,000 EUR
- EUR
7,000 EUR
- EUR
- EUR
- EUR
- EUR
EUR
- EUR
- EUR
- EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
- EUR
22 520 EUR
22 328 EUR
- EUR
- EUR
22 520 EUR
- EUR
192,000 EUR
- EUR
- EUR
32 804 EUR
- EUR
31 831 EUR
31 831 EUR
- EUR
973,000 EUR
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent
22 520 EUR
31 831 EUR
Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract]
Comprehensive income, attributable to non-controlling interests
- EUR
EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.